Acadia Pharmaceuticals | ACAD - 股本和储备



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 4.3B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


股本和储备 更改 日
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Biogen USD 18.85B 196.3M 2026-06
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cara Therapeutics USD 20.95M 6.92M 2025-12
Corcept Therapeutics USD 705.78M 67.79M 2026-06
Cytokinetics USD -826.57M 166.94M 2026-03
Eisai JPY 906.56B 7.57B 2026-06
Eli Lilly USD 31.2B 4.66B 2026-03
Incyte USD 6.34B 721.58M 2026-06
J&J USD 84.97B 3.78B 2026-06
Moderna USD 6.76B 647M 2026-06
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Pfizer USD 90.1B 3.63B 2026-03
Prothena USD 312.62M 32.14M 2026-03
PTC Therapeutics USD -165.36M 15.1M 2026-06
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03